Literature DB >> 29192390

EpCAM-based assays for epithelial tumor cell detection in cerebrospinal fluid.

Mark T J van Bussel1,2, Dick Pluim1, Mijke Bol3, Jos H Beijnen2,4, Jan H M Schellens1,2,4, Dieta Brandsma5.   

Abstract

The diagnosis of leptomeningeal metastases (LM) of solid tumors is complicated due to low sensitivities of both magnetic resonance imaging (MRI) and cytology. MRI has a sensitivity of 76% for the diagnosis of LM and cerebrospinal fluid (CSF) cytology has a sensitivity of 44-67% at first lumbar puncture which increases to 84-91% upon second CSF sampling. Epithelial cell adhesion molecule (EpCAM) is expressed by solid tumors of epithelial origin like non-small-cell lung cancer, breast cancer or ovarium cancer. Recently, a CELLSEARCH® assay and flow cytometry laboratory techniques have been developed to detect circulating tumor cells (CTCs) of epithelial origin in CSF. These laboratory techniques are based on capture antibodies labelled with different fluorescent tags against EpCAM. In this review, we provide an overview of the available laboratory techniques and diagnostic accuracy for tumor cell detection in CSF. The reported sensitivities of the EpCAM-based CTC assays for the diagnosis of LM across the different studies are highly promising and vary between 76 and 100%. An overview of the different EpCAM-based techniques for the enumeration of CTCs in the CSF is given and a comparison is made with CSF cytology for the diagnoses of LM from epithelial tumors.

Entities:  

Keywords:  CELLSEARCH®; Cerebrospinal fluid; Epithelial cell adhesion molecule; Flow cytometry; Leptomeningeal metastases

Mesh:

Substances:

Year:  2017        PMID: 29192390     DOI: 10.1007/s11060-017-2691-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  34 in total

1.  The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis.

Authors:  C S Straathof; H G de Bruin; D W Dippel; C J Vecht
Journal:  J Neurol       Date:  1999-09       Impact factor: 4.849

Review 2.  Leptomeningeal metastasis: a Response Assessment in Neuro-Oncology critical review of endpoints and response criteria of published randomized clinical trials.

Authors:  Marc Chamberlain; Riccardo Soffietti; Jeffrey Raizer; Roberta Rudà; Dieta Brandsma; Willem Boogerd; Sophie Taillibert; Morris D Groves; Emilie Le Rhun; Larry Junck; Martin van den Bent; Patrick Y Wen; Kurt A Jaeckle
Journal:  Neuro Oncol       Date:  2014-05-27       Impact factor: 12.300

3.  Presenting features and value of diagnostic procedures in leptomeningeal metastases.

Authors:  R J van Oostenbrugge; A Twijnstra
Journal:  Neurology       Date:  1999-07-22       Impact factor: 9.910

4.  Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival.

Authors:  Daniel F Hayes; Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; M Craig Miller; Jeri Matera; W Jeffrey Allard; Gerald V Doyle; Leon W W M Terstappen
Journal:  Clin Cancer Res       Date:  2006-07-15       Impact factor: 12.531

5.  Diagnostic and prognostic significance of flow cytometry immunophenotyping in patients with leptomeningeal carcinomatosis.

Authors:  D Subirá; M Simó; J Illán; C Serrano; S Castañón; R Gonzalo; J J Granizo; M Martínez-García; M Navarro; J Pardo; J Bruna
Journal:  Clin Exp Metastasis       Date:  2015-03-21       Impact factor: 5.150

Review 6.  Prognostic value of circulating tumor cells in metastatic breast cancer: a systemic review and meta-analysis.

Authors:  Q Lv; L Gong; T Zhang; J Ye; L Chai; C Ni; Y Mao
Journal:  Clin Transl Oncol       Date:  2015-08-11       Impact factor: 3.405

7.  Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients.

Authors:  W R Wasserstrom; J P Glass; J B Posner
Journal:  Cancer       Date:  1982-02-15       Impact factor: 6.860

8.  Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases.

Authors:  Akshal S Patel; Joshua E Allen; David T Dicker; Kristi L Peters; Jonas M Sheehan; Michael J Glantz; Wafik S El-Deiry
Journal:  Oncotarget       Date:  2011-10

9.  Meta-analysis of the prognostic value of circulating tumor cells detected with the CellSearch System in colorectal cancer.

Authors:  Xuanzhang Huang; Peng Gao; Yongxi Song; Jingxu Sun; Xiaowan Chen; Junhua Zhao; Huimian Xu; Zhenning Wang
Journal:  BMC Cancer       Date:  2015-03-30       Impact factor: 4.430

10.  Overexpression of syndecan-1, MUC-1, and putative stem cell markers in breast cancer leptomeningeal metastasis: a cerebrospinal fluid flow cytometry study.

Authors:  Iole Cordone; Serena Masi; Valentina Summa; Mariantonia Carosi; Antonello Vidiri; Alessandra Fabi; Alessia Pasquale; Laura Conti; Immacolata Rosito; Carmine Maria Carapella; Veronica Villani; Andrea Pace
Journal:  Breast Cancer Res       Date:  2017-04-11       Impact factor: 6.466

View more
  11 in total

1.  Quantification of leptomeningeal metastases from solid tumors remains a challenging issue.

Authors:  Dieta Brandsma; Martin J B van den Bent
Journal:  Neuro Oncol       Date:  2020-05-15       Impact factor: 12.300

2.  The joint detection of CEA and ctDNA in cerebrospinal fluid: an auxiliary tool for the diagnosis of leptomeningeal metastases in cancer.

Authors:  Yong Wang; Ningning Luo; Ye Gao; Yaqing Wu; Xueting Qin; Yingxue Qi; Tingting Sun; Rongjie Tao; Chuang Qi; Baoyan Liu; Shuanghu Yuan
Journal:  J Cancer Res Clin Oncol       Date:  2022-05-18       Impact factor: 4.553

Review 3.  Advances in the Diagnosis and Treatment of Leptomeningeal Disease.

Authors:  Akanksha Sharma; Justin T Low; Priya Kumthekar
Journal:  Curr Neurol Neurosci Rep       Date:  2022-05-19       Impact factor: 5.081

4.  Circulating Tumor Cells Detection in Patients with Early Breast Cancer Using MACS Immunomagnetic Flow Cytometry.

Authors:  Nasrin Karimi; Mana Oloomi; Zahra Orafa
Journal:  Avicenna J Med Biotechnol       Date:  2020 Jul-Sep

Review 5.  Neoplastic meningitis in solid tumors: from diagnosis to personalized treatments.

Authors:  Alessia Pellerino; Luca Bertero; Roberta Rudà; Riccardo Soffietti
Journal:  Ther Adv Neurol Disord       Date:  2018-03-07       Impact factor: 6.570

6.  Radiographic appearance of leptomeningeal disease in patients with EGFR-mutated non-small-cell lung carcinoma treated with tyrosine kinase inhibitors: a case series.

Authors:  Ugur Sener; Nassim Matin; Helena Yu; Andrew Lin; T Jonathan Yang; Rachna Malani
Journal:  CNS Oncol       Date:  2019-11-28

Review 7.  The Underlying Biology and Therapeutic Vulnerabilities of Leptomeningeal Metastases in Adult Solid Cancers.

Authors:  Matthew Dankner; Stephanie Lam; Theresa Degenhard; Livia Garzia; Marie-Christine Guiot; Kevin Petrecca; Peter M Siegel
Journal:  Cancers (Basel)       Date:  2021-02-10       Impact factor: 6.639

8.  [Auxiliary Diagnostic Value of Tumor Markers in the Cerebrospinal Fluid and Blood for Leptomeningeal Metastasis from Non-small Cell Lung Cancer].

Authors:  Yongjuan Lin; Huiying Li; Mingmin Huang; Zhenyu Yin; Jianqing Wu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2020-06-20

9.  Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications.

Authors:  Adrienne Boire; Dieta Brandsma; Priscilla K Brastianos; Emilie Le Rhun; Manmeet Ahluwalia; Larry Junck; Michael Glantz; Morris D Groves; Eudocia Q Lee; Nancy Lin; Jeffrey Raizer; Roberta Rudà; Michael Weller; Martin J Van den Bent; Michael A Vogelbaum; Susan Chang; Patrick Y Wen; Riccardo Soffietti
Journal:  Neuro Oncol       Date:  2019-05-06       Impact factor: 12.300

10.  Deciphering Biomarkers for Leptomeningeal Metastasis in Malignant Hemopathies (Lymphoma/Leukemia) Patients by Comprehensive Multipronged Proteomics Characterization of Cerebrospinal Fluid.

Authors:  Pablo Juanes-Velasco; Norma Galicia; Elisa Pin; Ricardo Jara-Acevedo; Javier Carabias-Sánchez; Rodrigo García-Valiente; Quentin Lecrevisse; Carlos Eduardo Pedreira; Rafael Gongora; Jose Manuel Sanchez-Santos; Héctor Lorenzo-Gil; Alicia Landeira-Viñuela; Halin Bareke; Alberto Orfao; Peter Nilsson; Manuel Fuentes
Journal:  Cancers (Basel)       Date:  2022-01-17       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.